Fig 2. Pharmacodynamics of FLC generic products compared with the innovator against C. albicans CIB-19177.

Data from two independent experiments were combined and analyzed by CFA. The innovator (Diflucan) was included in both experiments (42 animals), and Claris, Fresenius and Vitalis in one (21 animals per product). A single curve (solid black line) described the data better than individual ones, indicating that the generics were therapeutically equivalent to the innovator. The horizontal dotted line indicates the fungal load at the beginning of therapy (0 h).